Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), will participate in two upcoming investor conferences. The first is the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, featuring a fireside chat at 10:55 am ET. The second is the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, with a fireside chat at 10:00 am ET. Both sessions will be accessible via webcast on Altimmune's website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with notable products like pemvidutide (ALT-801).
Altimmune, Inc. (Nasdaq: ALT) reported its financial results for Q3 2022, revealing a net loss of $23.5 million, or $0.48 per share, an improvement from a $33.5 million loss in Q3 2021. The company holds $201.9 million in cash and equivalents as of September 30, 2022. Key upcoming milestones include topline data from a 24-week Phase 1b NAFLD trial expected in mid-December 2022 and interim results from the MOMENTUM Phase 2 obesity trial anticipated in Q1 2023. The company aims to leverage significant reductions in liver fat and body weight from its pemvidutide program.
Altimmune, Inc. (Nasdaq: ALT) will report its Q3 2022 financial results on November 10, 2022, followed by a management conference call at 8:30 am ET. The discussion will focus on financial performance and business updates. Live streaming of the call will be available on the company's Investor Relations website. Altimmune specializes in peptide-based therapeutics for obesity and liver diseases, with its lead candidate being pemvidutide, aimed at treating obesity and non-alcoholic steatohepatitis (NASH).
Altimmune, Inc. (Nasdaq: ALT) announced its upcoming scientific presentations at two conferences in November 2022. The first presentation, at the American Heart Association Scientific Sessions on November 5, will focus on the effects of Pemvidutide (ALT-801) on lipid mediators. The second, at the American Association for the Study of Liver Disease on November 7, will present results from a Phase 1b trial evaluating a dual receptor agonist's impact on liver fat reduction in patients with non-alcoholic fatty liver disease. Presentation materials will be accessible on Altimmune's website.
Altimmune, Inc. (Nasdaq: ALT) announced the successful completion of patient dosing for its Phase 2 MOMENTUM trial, evaluating the efficacy and safety of pemvidutide, a dual receptor agonist for obesity and NASH. This multicenter trial involves 320 subjects randomized to receive various doses of pemvidutide or placebo over 48 weeks, focusing on weight change and metabolic profiles. The trial's 24-week interim analysis is anticipated in Q1 2023, marking a significant milestone in pemvidutide's development.
Altimmune, Inc. (ALT) announced positive results from a 12-week Phase 1b study of pemvidutide for non-alcoholic fatty liver disease (NAFLD). All dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved primary endpoints, with a 68.5% relative reduction in liver fat at the 1.8 mg dose. Subjects without diabetes saw a mean weight loss of 4.9% (placebo-adjusted 4.7%). The treatment was well-tolerated, mainly with mild gastrointestinal events, and no serious adverse events were reported. Next steps include data from a 24-week NAFLD trial and interim results from the MOMENTUM obesity trial.
Altimmune, Inc. (Nasdaq: ALT) reported its financial results for the second quarter of 2022, with a net loss of $20.1 million or $0.42 per share, an improvement from a net loss of $24.8 million in Q2 2021. The company reported minimal revenue due to the discontinuation of T-COVID and NasoShield programs. Altimmune is advancing its pemvidutide clinical trials, with topline data from a 12-week Phase 1b trial in subjects with obesity/overweight and non-alcoholic fatty liver disease (NAFLD) expected in mid-September 2022.
Research and development expenses increased to $16 million, primarily due to pemvidutide development.
Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2022 financial results on August 11, 2022, followed by a conference call at 8:30 am E.T. to discuss these results and provide a business update. The call will be accessible via webcast on Altimmune's Investor Relations website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide, targeting obesity and NASH. Altimmune is also advancing its HepTcell™ immunotherapeutic for chronic hepatitis B.
Altimmune presented the results of its Phase 1 clinical trial for pemvidutide at the 2022 International Liver Congress, focusing on obesity and NASH treatment. The presentation, titled "Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat", was delivered by Dr. Stephen A. Harrison on June 25, 2022. The study displayed significant findings, earning a spot in the congress's Best of International Liver Congress. Additionally, Dr. Scott Harris will discuss study findings at a press conference on June 24, 2022.
Altimmune, Inc. (Nasdaq: ALT) announced its participation in two upcoming investor conferences in June 2022. The events include the Jefferies 2022 Global Healthcare Conference on June 10 at 10:00 am ET and the JMP Securities Life Sciences Conference on June 16 at 9:00 am ET, both held in New York. Interested investors can access the webcast via the company’s website. Altimmune develops novel therapeutics for obesity and liver diseases.